1.36

2.86% -0.04

Pre-market: 1.40 0.04 +2.94%

Coherus Oncology Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Oncology Inc stock is traded at $1.36, with a volume of 707.93K. It is down -2.86% in the last 24 hours and down -13.38% over the past month. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Previous Close:

$1.40

Open:

$1.42

24h Volume:

707.93K

Relative Volume:

0.61

Market Cap:

$209.78M

Revenue:

$42.17M

Net Income/Loss:

$-183.12M

P/E Ratio:

-0.9339

EPS:

-1.4562

Net Cash Flow:

$-138.51M

1W Performance:

-4.23%

1M Performance:

-13.38%

6M Performance:

-2.16%

1Y Performance:

+78.55%

1-Day Range:

$1.36

$1.45

1-Week Range:

$1.33

$1.485

52-Week Range:

$0.71

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Name

Coherus Oncology Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

145

Twitter

@coherus_bio

Next Earnings Date

2026-08-06

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Oncology Inc	1.36	209.78M	42.17M	-183.12M	-138.51M	-1.4562
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-26	Initiated	Oppenheimer	Outperform
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Oncology Inc Stock (CHRS) Latest News

Jun 15, 2026

Coherus Oncology, Inc. 8-K SEC Filing June 12, 2026 – Entity Information, Common Stock, NASDAQ, and Exhibit Letter from Ernst & Young LLP 18205556 – Minichart - Minichart

Jun 15, 2026

Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young - Investing.com

Jun 15, 2026

[8-K] Coherus Oncology, Inc. Reports Material Event - Stock Titan

Jun 15, 2026

Jun 09, 2026

Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant - Stock Titan

Jun 09, 2026

[Form 4] Coherus Oncology, Inc. Insider Trading Activity - Stock Titan

Jun 09, 2026

Jun 04, 2026

CHRS: Immuno-oncology pipeline advances with key data and global deals expected in 6–18 months - TradingView

Jun 04, 2026

CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill

Jun 04, 2026

Jun 03, 2026

CHRS Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Negative Stock ReactionEarnings Surprise Report - newsline.com

Jun 03, 2026

Jun 02, 2026

Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants - Stock Titan

Jun 02, 2026

Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59 - Stock Titan

Jun 02, 2026

Coherus Biosciences Announces 2026 Stockholder Meeting Results - The Globe and Mail

Jun 02, 2026

Jun 01, 2026

Coherus Oncology, Inc. 8-K SEC Filing: Company Details, Stock Information, and Compliance Disclosures (May 27, 2026) - Minichart

Jun 01, 2026

Coherus Oncology shareholders approve director elections and equity plan changes - Investing.com Canada

Jun 01, 2026

Coherus Oncology shareholders approve director elections and equity plan changes By Investing.com - Investing.com South Africa

Jun 01, 2026

Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing - Stock Titan

Jun 01, 2026

May 31, 2026

Coherus Oncology (CHRS) reports Q1 loss, lags revenue estimates - MSN

May 31, 2026

May 28, 2026

TD Cowen Maintains Coherus Oncology(CHRS.US) With Buy Rating - Moomoo

May 28, 2026

May 27, 2026

CHRS: All proposals passed except the stock option price reduction, which was adjourned - TradingView

May 27, 2026

CHRS: Directors and key proposals were approved; stock option vote adjourned to May 29, 2026 - TradingView

May 27, 2026

May 25, 2026